✦ LIBER ✦

The Inhaled Steroid Treatment as Regular Therapy in Early Asthma (START) Study: Rationale and Design

✍ Scribed by Romain A. Pauwels; William W. Busse; Paul M. O'Byrne; Sören Pedersen; Wan C. Tan; Yu-Zhi Chen; Stefan V. Ohlsson; Anders Ullman

Book ID: 114186853
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 94 KB
Volume: 22
Category: Article
ISSN: 0197-2456
DOI: 10.1016/s0197-2456(01)00144-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Inhaled Steroid Treatment As Regular

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) follow-up study does not support early and daily treatment

✍ Gereda, Jose E.; Baena-Cagnani, Carlos 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Safety and tolerability of inhaled budes

Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial

✍ Michael Silverman; Albert L. Sheffer; Patricia V Díaz; Bengt Lindberg 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

The Inhaled Steroid Treatment As Regular

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: Effectiveness of early intervention with budesonide in mild persistent asthma

✍ Busse, William W.; Pedersen, Søren; Pauwels, Romain A.; Tan, Wan C.; Chen, Yu-Zh 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Early intervention of recent onset mild

Early intervention of recent onset mild persistent asthma in children aged under 11 yrs: the Steroid Treatment As Regular Therapy in early asthma (START) trial

✍ Yu-Zhi Chen; William W. Busse; Søren Pedersen; Wan Tan; Carl-Johan Lamm; Paul M. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Montelukast or salmeterol combined with

Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial)

✍ L. BJERMER; H. BISGAARD; J. BOUSQUET; L.M. FABBRI; A. GREENING; T. HAAHTELA; S.T 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 199 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

✍ C. Warren Olanow; Robert A. Hauser; Joseph Jankovic; William Langston; Anthony L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

## Abstract A neuroprotective therapy is the single most important unmet medical need in Parkinson's disease. Several promising agents in the laboratory have been tested in the clinic, but none has been established in clinical trials to have a disease modifying effect despite positive results becau